2005 © Oxford University Press
Spermatogenesis After Cancer Treatment: Damage and Recovery
Affiliation of authors: Department of Endocrinology, Christie Hospital NHS Trust, Withington, Manchester, United Kingdom
Correspondence to: Professor S. M. Shalet, Department of Endocrinology, Christie Hospital NHS Trust, Withington, Manchester, UK M20 4BX (e-mail: stephen.m.shalet{at}man.ac.uk).
Treatment with cytotoxic chemotherapy and radiotherapy is associated with significant gonadal damage in men, and alkylating agents are the most common agents implicated. The vast majority of men receiving procarbazine-containing regimens for the treatment of lymphomas are rendered permanently infertile, whereas treatment with doxorubicin hydrochloride (Adriamycin), bleomycin, vinblastine, and dacarbazine appears to have a significant advantage, with a return to normal fertility in the vast majority of patients. Cisplatin-based chemotherapy for testicular cancer results in temporary azoospermia in most men, with a recovery of spermatogenesis in about 50% of the patients after 2 years and 80% after 5 years. The germinal epithelium is very sensitive to radiation-induced damage, with changes to spermatogonia following as little as 0.2 Gy. Testicular doses of less than 0.2 Gy had no significant effect on FSH levels or sperm counts, whereas doses between 0.2 and 0.7 Gy caused a transient dose–dependent increase in FSH and reduction in sperm concentration, with a return to normal values within 12–24 months. No radiation dose threshold has been defined above which permanent azoospermia is inevitable; however, doses of 1.2 Gy and above are likely to be associated with a reduced risk of recovery of spermatogenesis; the time to recovery, if it is to occur, is also likely to be dose dependent.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. O. Ilbey, E. Ozbek, M. Cekmen, A. Simsek, A. Otunctemur, and A. Somay Protective effect of curcumin in cisplatin-induced oxidative injury in rat testis: mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways Hum. Reprod., July 1, 2009; 24(7): 1717 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, D. J. Magid, B. Wells, S. H. Sung, A. E. Cassidy-Bushrow, R. T. Greenlee, R. D. Langer, T. A. Lieu, K. L. Margolis, F. A. Masoudi, et al. The Cardiovascular Research Network: A New Paradigm for Cardiovascular Quality and Outcomes Research Circ Cardiovasc Qual Outcomes, November 1, 2008; 1(2): 138 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Marcon, B. F. Hales, and B. Robaire Reversibility of the Effects of Subchronic Exposure to the Cancer Chemotherapeutics Bleomycin, Etoposide, and Cisplatin on Spermatogenesis, Fertility, and Progeny Outcome in the Male Rat J Androl, July 1, 2008; 29(4): 408 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A.E. van der Kaaij, N. Heutte, N. Le Stang, J. M.M. Raemaekers, A. H.M. Simons, P. Carde, E. M. Noordijk, C. Ferme, J. Thomas, H. Eghbali, et al. Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte J. Clin. Oncol., July 1, 2007; 25(19): 2825 - 2832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Vaisheva, G. Delbes, B. F. Hales, and B. Robaire Effects of the Chemotherapeutic Agents for Non-Hodgkin Lymphoma, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), on the Male Rat Reproductive System and Progeny Outcome J Androl, July 1, 2007; 28(4): 578 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wyns, M. Curaba, B. Martinez-Madrid, A. Van Langendonckt, W. Francois-Xavier, and J. Donnez Spermatogonial survival after cryopreservation and short-term orthotopic immature human cryptorchid testicular tissue grafting to immunodeficient mice Hum. Reprod., June 1, 2007; 22(6): 1603 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Board, A. Karva, R. E. Board, A. K. Gambhir, and M. L. Porter The prophylaxis and treatment of heterotopic ossification following lower limb arthroplasty J Bone Joint Surg Br, April 1, 2007; 89-B(4): 434 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Achille, Z. Rosberger, R. Robitaille, S. Lebel, J.-P. Gouin, B. D. Bultz, and P. T.K.Chan Facilitators and obstacles to sperm banking in young men receiving gonadotoxic chemotherapy for cancer: the perspective of survivors and health care professionals Hum. Reprod., December 1, 2006; 21(12): 3206 - 3216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Lee, L. R. Schover, A. H. Partridge, P. Patrizio, W. H. Wallace, K. Hagerty, L. N. Beck, L. V. Brennan, and K. Oktay American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients J. Clin. Oncol., June 20, 2006; 24(18): 2917 - 2931. [Abstract] [Full Text] [PDF]
|
|